Next-Generation SINE Compounds
Various Cancers
Pre-clinical / Early ClinicalDiscovery/Development
Key Facts
Indication
Various Cancers
Phase
Pre-clinical / Early Clinical
Status
Discovery/Development
Company
About Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Retifanlimab | Eli Lilly | Phase 2/3 |
| Imfinzi (durvalumab) | AstraZeneca | Approved |
| Lynparza (olaparib) | Merck | Commercial |
| Oncology Portfolio | Pfizer | Phase 1-3 |
| PD-1 Inhibitor | Akeso | Phase 2/3 |
| Mitoxantrone Liposome | CSPC Pharmaceutical Group Limited | Phase 3 |
| Biosimilar Bevacizumab | Cipla | Commercial |
| Tazverik (tazemetostat) | Eisai | Commercial |
| Oncology Generics | Aurobindo Pharma | Commercial |
| Opdivo (nivolumab) | Ono Pharmaceutical | Approved |
| Oncology APIs (e.g., Sorafenib, Lenalidomide) | Laurus Labs | Commercial/Filed |
| Tumor Marker Portfolio (PSA, CA125, etc.) | H.U. Group Holdings | Commercial |